Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...

This study provides valuable guidance for doctors and patients when choosing diabetes medications. It confirms that ...

A LOVED-UP mum’s bid to shine in her wedding dress went wrong after using a pharmacy-bought ‘fat jab’. Stephanie Hill decided ...

The global antidiabetics market is on a strong growth trajectory, with sales projected to soar from USD 106.3 billion in 2024 to USD 298.2 billion by 2034. This substantial increase reflects a robust ...

Novo Nordisk, for instance, developed the drug liraglutide, which was a daily injection, and long-acting GLP-1 agonists such ...

For details, see the “What should be considered before taking Victoza?” section. Diabetes affects your metabolism. It causes high blood sugar due to problems making or using insulin in your body.

Novo Nordisk’s GLP-1 agonist Victoza has become the first non-insulin drug to be approved in the US as a treatment for type 2 diabetes in children for almost two decades.

"The action of liraglutide in patients with type 2 diabetes is largely due to an increase in insulin secretion from the pancreas,," Dandona explains, "But since type 1 diabetics have no insulin ...

Liraglutide consists of an agonist for the GLP-1 receptor, which has physiological effects such as increasing insulin release, reducing glucagon release, and decreasing hunger sensations.

We found that insulin treatment aggravated hepatic steatosis and oxidative stress in Zucker diabetic fatty (ZDF) rats. In addition to glycaemic control, we demonstrated the stimulatory role of ...

Markets are nervous now that a second wave of Covid-19 is sweeping across much of the world and US technology stocks, which have spearheaded the rally, are trading at eye-watering valuations.